South Korea's Pharma-Biotech Companies to Invest US$10.7 Billion

Researched by Industrial Info Resources (Sugar Land, Texas)--Industrial Info is tracking 426 active pharmaceutical and biotech projects in South Korea with a total investment value of US$10.7 billion. Among them, Lotte Biologics (Seoul, South Korea) and Samsung Biologics Company Limited (Songdo, South Korea) account for the largest investment in the contract development and manufacturing organization (CDMO) plants. A Lotte Biologics plant is currently under construction and is scheduled to be completed in 2027; subsequent expansions will follow (total investment of approximately US$3 billion). For Samsung Biologics, the expansion of its sixth plant is scheduled for 2026 (approximately US$690 million). Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical-Biotech Project Database can learn more by viewing the related project reports and plant profiles.

Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).